Abstract
This chapter provides an overview of some of the complex ethical, legal, and social issues associated with advances in genomics and molecular medicine, such as equity in access to genetic information and services, use of genetic information in nonhealth-related settings, and genetic discrimination. It is hoped that this discussion will stimulate future discussions about these and other issues that are just beginning to emerge in the exciting, ever-changing world of genomic health care. Discussions such as these are critical to the development of appropriate policies and legislation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected References
Brower V. Genomics and health care. How genomics medicine is translated into better health care largely depends on how physicians handle this information. EMBO Rep 2004; 5: 131–133.
Chen WY, Garber JE, Higham S, et al. BRCA1/2 genetic testing in the community setting. J Clin Oncol 2002; 20: 4485–4492.
Christian SM, Kieffer SA, Leonard NJ. Medical genetics and patient use of the Internet. Clin Genet 2001; 60: 232–236.
Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003; 349: 562–569.
Collins FS, Green ED, Guttmacher AE, Guyer MS, US National Human Genome Research Institute. A vision for the future of genomics research. Nature 2003; 422: 835–847.
Collins FS, Guttmacher AE. Genetics moves into the medical mainstream. JAMA 2001; 286: 2322–2324.
Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 2001; 285: 540–544.
Freedman AN, Wideroff L, Olson L, et al. US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet 2003; 120A: 63–71.
GeneWatch UK. Genetic testing and the body shop. http://www.genewatch.org/HumanGen/Tests/BodyShop.htm. Accessed July 20, 2004.
Gollust SE, Wilfond BS, Hull SC. Direct-to-consumer sales of genetic services on the internet. Genet Med 2003; 5: 332–337.
Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003; 349: 996–998.
Hampton T. Breast cancer gene chip study under way: can new technology help predict treatment success? JAMA 2004; 291: 2927–2930.
Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 77–84.
Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93:1633–1637.
Hayden MR. Predictive testing for Huntington’s disease: the calm after the storm. Lancet 2000; 356: 1944, 1945.
Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003;5: 261–268.
Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159–164.
Miller PS. Genetic discrimination in the workplace. J Law Med Ethics 1998; 26: 189–197.
O’Neill O. Informed consent and genetic information. Stud Hist Philos Biol Biomed Sci 2001; 32:689–704.
Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002; 11: 79–87.
Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003:348: 1866–1874.
Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004; 350: 1814–1816.
Robertson JA. The $1000 genome: ethical and legal issues in whole genome sequencing of individuals. Am J Bioeth 2003; 3: W35–W42.
Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857–865.
Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA 1/BRCA 2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823–1829.
Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet 2004; 363: 1633–1641.
Singer E, Antonucci T, Van Hoewyk J. Racial and ethnic variations in knowledge and attitudes about genetic testing. Genet test 2004; 8: 31–43.
Thompson HS, Valdimarsdottir HB, Jandorf L, Redd W. Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina, and Caucasian women. Patient Educ Couns 2003; 51: 217–227.
van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999–2009.
Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003; 138: 1323–1328.
Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003; 3: 194–196.
Williams-Jones B. Where there’s a web, there’s a way: commercial genetic testing and the Internet. Community Genet 2003; 6: 46–57.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this chapter
Cite this chapter
Van Riper, M. (2006). Ethical, Legal, and Social Implications. In: Runge, M.S., Patterson, C. (eds) Principles of Molecular Medicine. Humana Press. https://doi.org/10.1007/978-1-59259-963-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-963-9_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-202-5
Online ISBN: 978-1-59259-963-9
eBook Packages: MedicineMedicine (R0)